Pivotal Trials in the Realm of Ovarian Cancer
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study
Efficacy | ZEJULA (niraparib) for HCPs
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer | PPT
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | Oncology and Therapy
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Efficacy of Niraparib by Timing of Surgery and Residual Disease: a Post Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-301
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Efficacy | ZEJULA (niraparib) for HCPs
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Estudo PRIMA: niraparib demonstra benefício na PFS a longo prazo no tratamento de 1.ª linha do cancro do ovário
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
TESARO Pioneers Summit - ppt download
Treatment Considerations With Niraparib
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
